Zhang Yong-Gang, Li Jun, Li Yu-Guang, Wei Rui-Hong
Department of Cardiovascular Diseases, First Affiliated Hospital, Shantou University Medical College, Shantou, China.
J Hypertens. 2008 Jun;26(6):1119-26. doi: 10.1097/HJH.0b013e3282fa1412.
Urotensin II is a new potent vasoconstrictor. Nevertheless, little is known about its effects on the activation of adventitial fibroblasts.
To explore the effects of urotensin II on phenotypic differentiation, migration, and collagen I synthesis of rat aortic adventitial fibroblasts.
Growth-arrested adventitial fibroblasts were incubated in serum-free medium with urotensin II and some inhibitors of signal transduction pathways. The alpha-smooth muscle-actin expression, collagen I synthesis and migration of adventitial fibroblasts induced by urotensin II were evaluated by western blot, enzyme-linked immunosorbant assay, and the transwell technique, respectively.
Urotensin II induced the [alpha]-smooth muscle-actin expression in a dose-dependent and time-dependent manner, with maximal effect at a concentration of 10(-8) mol/l at 24 h (79.9%); it also caused a dose-dependent increase in collagen I synthesis, with maximal effect at a concentration of 10(-7) mol/l (42.6%). The Ca2+ channel blocker nicardipine (10(-5) mol/l), protein kinase C inhibitor H7 (10(-5) mol/l), Rho protein kinase inhibitor Y-27632 (10(-5) mol/l), calcineurin inhibitor cyclosporine A (10(-5) mol/l), and mitogen-activated protein kinase inhibitor PD98059 (10(-5) mol/l) inhibited urotensin II-induced increases in [alpha]-smooth muscle-actin expression and collagen synthesis. Meanwhile, urotensin II stimulated the migration of adventitial fibroblasts dose dependently, with maximal effect at a concentration of 10(-8) mol/l, which was 5.7-fold greater than that of the control. This effect could also be inhibited by PD98059, H7, cyclosporine A, and Y-27632 but not nicardipine.
Urotensin II may stimulate adventitial fibroblasts phenotypic conversion, migration, and collagen I synthesis through the protein kinase C, mitogen-activated protein kinase, calcineurin, Rho kinase, and/or Ca2+ signal transduction pathways, contributing to the development of vascular remodeling through adventitial fibroblasts activation.
尾加压素II是一种新型强效血管收缩剂。然而,关于其对外膜成纤维细胞激活的影响知之甚少。
探讨尾加压素II对大鼠主动脉外膜成纤维细胞表型分化、迁移及I型胶原合成的影响。
将生长停滞的外膜成纤维细胞与尾加压素II及一些信号转导通路抑制剂在无血清培养基中共同孵育。分别采用蛋白质印迹法、酶联免疫吸附测定法及Transwell技术评估尾加压素II诱导的外膜成纤维细胞α-平滑肌肌动蛋白表达、I型胶原合成及迁移情况。
尾加压素II以剂量和时间依赖性方式诱导α-平滑肌肌动蛋白表达,在24小时时浓度为10(-8) mol/L时作用最强(79.9%);它还引起I型胶原合成呈剂量依赖性增加,在浓度为10(-7) mol/L时作用最强(42.6%)。钙通道阻滞剂尼卡地平(10(-5) mol/L)、蛋白激酶C抑制剂H7(10(-5) mol/L)、Rho蛋白激酶抑制剂Y-27632(10(-5) mol/L)、钙调神经磷酸酶抑制剂环孢素A(10(-5) mol/L)及丝裂原活化蛋白激酶抑制剂PD98059(10(-5) mol/L)均可抑制尾加压素II诱导的α-平滑肌肌动蛋白表达及胶原合成增加。同时,尾加压素II剂量依赖性地刺激外膜成纤维细胞迁移,在浓度为10(-8) mol/L时作用最强,比对照组高5.7倍。此作用也可被PD98059、H7、环孢素A及Y-27632抑制,但不受尼卡地平抑制。
尾加压素II可能通过蛋白激酶C、丝裂原活化蛋白激酶、钙调神经磷酸酶、Rho激酶和/或钙信号转导通路刺激外膜成纤维细胞表型转化、迁移及I型胶原合成,通过激活外膜成纤维细胞促进血管重塑的发展。